OGN 250516 12.50C(OGN250516C12500) Stock Price Today

0.55
+0.11+25.00%

15min DelayClose Apr 24 16:00 ET

0.60High0.26Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Teddy123

Apr 1 19:55

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

$Organon & Co (OGN.US)$ $Biogen (BIIB.US)$
Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal

Teddy123

Mar 28 18:19

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

$Organon & Co (OGN.US)$
Major Win: Organon's Breast Cancer Drug Gets Critical EMA Validation After Trial Success

Daily Investors

Mar 10 20:56

OGN's PDUFA Date: A Potential Catalyst for a Cataclysmic Spike?
Tomorrow is a pivotal day for Organogenesis Holdings Inc. (OGN), a regenerative medicine company focused on wound care, surgical and sports medicine. The company is awaiting a decision from the U.S. Food and Drug Administration (FDA) on its Biologics License Application (BLA) for FortaFlex, a novel treatment for partial-thickness rotator cuff tears. This crucial juncture, known as the PDUFA date (Prescription Drug User Fee Act), cou...

Teddy123

Mar 8 22:59

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Olde

$Organon & Co (OGN.US)$
Can This Skin Treatment Work for Months After Stopping? New Clinical Data Reveals Surprising Results

Jaguar8

Oct 28, 2024 21:26

NEWS

$Organon & Co (OGN.US)$
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%
The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.
BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global health...

OGN250516C12500

News

Comments